Holen Sie sich die Stockscreener-App
86.80
1.80%
-1.59
Schlusskurs vom Vortag:
$88.39
Offen:
$89.22
24-Stunden-Volumen:
1.30M
Relative Volume:
2.53
Marktkapitalisierung:
$4.81B
Einnahmen:
$76.81M
Nettoeinkommen (Verlust:
$-162.42M
KGV:
-29.03
EPS:
-2.99
Netto-Cashflow:
$-122.49M
1W Leistung:
+2.03%
1M Leistung:
+19.38%
6M Leistung:
+53.19%
1J Leistung:
+4.70%
1-Tages-Spanne:
$86.12
$90.41
1-Wochen-Bereich:
$83.33
$90.41
52-Wochen-Spanne:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Vergleichen Sie ACLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
86.80 | 4.90B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-10-30 | Eingeleitet | TD Cowen | Outperform |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-05-18 | Eingeleitet | Truist | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-14 | Eingeleitet | Stifel | Buy |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-13 | Fortgesetzt | BofA Securities | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-27 | Eingeleitet | Needham | Buy |
| 2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-03-01 | Eingeleitet | BofA Securities | Buy |
| 2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Analyzing recovery setups for Arcellx Inc. investors2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Arcellx (NASDAQ:ACLX) Rating Lowered to Hold at Cantor Fitzgerald - MarketBeat
Automated trading signals detected on Arcellx Inc.July 2025 Update & Verified Momentum Watchlists - newser.com
Using data filters to optimize entry into Arcellx Inc.Market Weekly Review & Expert Curated Trade Ideas - newser.com
Is Arcellx Inc. showing signs of accumulationWeekly Market Summary & Fast Entry High Yield Tips - newser.com
Arcellx assumed with a Neutral at Cantor Fitzgerald - TipRanks
Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook - Yahoo Finance
Arcellx's (ACLX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
ACLX: Cantor Fitzgerald Assumes Coverage with Neutral Rating | A - GuruFocus
What analyst consensus says on Arcellx Inc. stockWeekly Gains Report & Reliable Intraday Trade Plans - newser.com
Arcellx Inc Stock Analysis and ForecastIndustrial Stocks Review & Free Exceptional Market Positioning - earlytimes.in
CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insider Selling: Michelle Gilson Sells 5,946 Shares of Arcellx Inc (ACLX) - GuruFocus
Arcellx CFO Gilson sells $511k in ACLX stock - Investing.com
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position - TipRanks
Arcellx (NASDAQ:ACLX) Biggest Nasdaq Stocks Mirror Biotech Progress - Kalkine Media
Could Analyst Optimism on Neurotoxicity Give Arcellx (ACLX) an Edge in CAR-T Competition? - Sahm
Will Arcellx Inc. see short term momentumEarnings Recap Summary & Growth Focused Stock Reports - newser.com
Published on: 2025-10-05 04:40:22 - newser.com
A Fresh Look at Arcellx (ACLX) Valuation Following Scotiabank’s Regulatory Optimism and CAR-T Therapy Developments - Sahm
Will Arcellx Inc. bounce back from current supportMarket Movers & Fast Entry High Yield Tips - newser.com
What moving averages say about Arcellx Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
BofA Securities Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $112 - 富途牛牛
Christopher Heery Sells 21,034 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx CMO Heery sells $5851 in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx CMO Heery sells $5851 in ACLX stock - Investing.com India
What drives Arcellx Inc stock priceEx-Dividend Date Alerts & Budget Friendly Growth - earlytimes.in
Using portfolio simulators with Arcellx Inc. includedPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Arcellx CMO Heery sells $993k in ACLX stock - Investing.com India
Arcellx CMO Heery sells $993k in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx (NASDAQ:ACLX) Insider Sells $993,167.52 in Stock - MarketBeat
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $121 - 富途牛牛
Atle Fund Management AB Sells 18,439 Shares of Arcellx, Inc. $ACLX - MarketBeat
Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval - TipRanks
Strs Ohio Acquires New Stake in Arcellx, Inc. $ACLX - MarketBeat
Christopher Heery Sells 300 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx (NASDAQ:ACLX) Insider Christopher Heery Sells 3,343 Shares - MarketBeat
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arcellx Inc-Aktie (ACLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Oct 06 '25 |
Sale |
86.22 |
1,064 |
91,733 |
13,830 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):